A Study of LY2835219 in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:1/9/2019
Start Date:October 2014
End Date:November 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects

The aim of this two-period study is to compare how much of the study drug gets into the blood
stream when it is given as a single oral dose and when it is given as a single oral dose in
combination with rifampin (a Food and Drug Administration [FDA] approved antibiotic that is
used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other
infections). Each participant will complete both study periods.

The study will last about 34 days. Screening is required within 28 days before study drug is
given.


Inclusion Criteria:

- Overtly healthy sterile males or surgically sterile females or postmenopausal females

- Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m^2)

Exclusion Criteria:

- Have participated in a clinical trial involving investigational product within the
last 30 days

- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
investigator, increases the risks associated with participating in the study

- Have an abnormal blood pressure

- Show evidence of human immunodeficiency virus (HIV), hepatitis B or hepatitis C

- Have donated blood of more than 500 milliliters (mL) within the last month

- Have used or intend to use over-the-counter or prescription medication including
herbal medications within 7 days prior to dosing or during the study
We found this trial at
1
site
Clinical Trial Facility in Dallas Texas
Dallas, Texas 75390
?
mi
from
Dallas, TX
Click here to add this to my saved trials